Ryogen Licenses Human Aminopeptidase P Gene Patent to Invitrogen
Advertisement
Ryogen LLC announced that the company have entered into a nonexclusive license agreement with Invitrogen Corporation, whereby Invitrogen has licensed from Ryogen the patent directed to the clinically important Aminopeptidase P gene.
The US Patent (No. 6,399,349) titled "Human Aminopeptidase P Gene," which is the subject of the License Agreement, covers the XPNPEP2 gene sequenced by Dr. James Ryan, Chief Scientist of Ryogen LLC. XPNPEP2 codes for the membrane-bound aminopeptidase P (AmP). This protein is a significant marker for hypertension, angioedema, rejection of kidney transplants, certain tumors and other diseases. The patent covers the cDNA and gDNA sequences encoding AmP, a method of producing recombinant AmP, diagnostics for detecting AmP abnormalities, and prevention and treatment of medical conditions, associated with the mutation of the AmP gene.
Other news from the department business & finance
Most read news
More news from our other portals
See the theme worlds for related content
Last viewed contents
Big Pharma seeks to insulate itself from impact of ‘patent cliff’
Induced pluripotent stem cells reveal causes of disease - Using single-cell analyses, researchers systematically searched for correlations between individual genetic variants in induced pluripotent stem cells
For cells, some shapes are easier to swallow than others
